Famciclovir
- Generic Name
- Famciclovir
- Brand Names
- Famvir
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19N5O4
- CAS Number
- 104227-87-4
- Unique Ingredient Identifier
- QIC03ANI02
- Background
Famciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles). Famciclovir is a prodrug of penciclovir with higher oral bioavailability.
- Indication
For the treatment of acute herpes zoster (shingles). Also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients.
- Associated Conditions
- Herpes Zoster, Recurrent Genital Herpes (RGH), Recurrent Herpes Labialis
- Associated Therapies
- -
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
- Conditions
- Interventions
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1179
- Registration Number
- NCT00306787
- Locations
- 🇺🇸
Providence Clinical Research, Burbank, California, United States
🇺🇸Women's Medical Research Group, LLC, Clearwater, Florida, United States
🇺🇸UNC Clinical Research., Raleigh, North Carolina, United States
A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis
- Conditions
- First Posted Date
- 2005-11-03
- Last Posted Date
- 2007-12-10
- Lead Sponsor
- Novartis
- Registration Number
- NCT00248144
RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis
- Registration Number
- NCT00219310
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1461
- Registration Number
- NCT00171990
- Locations
- 🇦🇺
Novartis Investigative Site, North Ryde, Australia
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
- Conditions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis
- Registration Number
- NCT00129818
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸IU Center for Clinical STD Research, Indianapolis, Indiana, United States
Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection
- First Posted Date
- 2004-12-03
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT00098059
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Children's Medical Center of Dallas, Dallas, Texas, United States
🇺🇸Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
- Conditions
- First Posted Date
- 2004-12-03
- Last Posted Date
- 2007-09-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 76
- Registration Number
- NCT00098046
- Locations
- 🇵🇦
Novartis Investigational Site, David, Chiriqui, Panama
🇺🇸Columbia University Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.